Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Lunit Inc., a South Korean AI-powered cancer diagnostics company, has partnered with global biopharma giant AstraZeneca plc. to jointly enter the AI...
A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...
South Korea's medical AI company Lunit announced on Friday it will participate in the US President Joe Biden's cancer-conquering project Cancer Moon...
South Korea's Coreline Soft, a maker of artificial intelligence (AI)-based imaging diagnostic materials, on Wednesday said it will sell its chest di...
South Korea's Qurient Co. announced on Monday that it signed a research and development agreement with the US government agency National Cancer Inst...
Clinomics, a South Korean biotech company specializing in liquid biopsies, on Thursday said it developed equipment that can detect four types of l...
South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...
Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...
South Korea’s Hanmi Pharmaceutical Co. is set to launch its blockbuster high blood pressure drug Amosartan in China, the world’s largest...